A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2027-09-24

Summary

Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.

• Phase: PHASE2

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: bictegravir, emtricitabine, tenofovir alafenamide, drug combination; islatravir; ulonivirine